推荐产品
product name
烟酰胺, ≥98% (HPLC), powder
品質等級
化驗
≥98% (HPLC)
形狀
powder
顏色
white
mp
128-131 °C (lit.)
應用
cell analysis
SMILES 字串
NC(=O)c1cccnc1
InChI
1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)
InChI 密鑰
DFPAKSUCGFBDDF-UHFFFAOYSA-N
基因資訊
human ... PARP1(142) , SIRT2(22933)
正在寻找类似产品? 访问 产品对比指南
應用
用作某些酶的辅助因子
生化/生理作用
烟酰胺是维生素B3的酰胺衍生物,是PARP抑制剂
特點和優勢
该化合物是基因调控研究推荐产品。点击此处 ,查看更多基因调控精选产品。想要了解有关生物活性小分子在其他研究领域应用的更多信息,请访问 sigma.com/discover-bsm。
儲存和穩定性
本品可在室温和干燥条件下密封保存。
訊號詞
Warning
危險聲明
危險分類
Eye Irrit. 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 1
閃點(°F)
302.0 °F - closed cup
閃點(°C)
150 °C - closed cup
個人防護裝備
dust mask type N95 (US), Eyeshields, Gloves
其他客户在看
Cell reports, 28(6), 1538-1550 (2019-08-08)
Ras GTPases are mutated at codons 12, 13, and 61, with different frequencies in KRas, HRas, and NRas and in a cancer-specific manner. The G13D mutant appears in 25% of KRas-driven colorectal cancers, while observed only rarely in HRas or
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(32), 4067-4075 (2013-10-02)
Open-label, phase III trial evaluating whether sunitinib was superior or equivalent to sorafenib in hepatocellular cancer. Patients were stratified and randomly assigned to receive sunitinib 37.5 mg once per day or sorafenib 400 mg twice per day. Primary end point
The Lancet. Oncology, 14(6), 552-562 (2013-04-20)
In a phase 3 trial comparing the efficacy and safety of axitinib versus sorafenib as second-line treatment for metastatic renal cell carcinoma, patients given axitinib had a longer progression-free survival (PFS). Here, we report overall survival and updated efficacy, quality
Nature chemical biology, 9(11), 693-700 (2013-10-01)
Sirtuins, a family of histone deacetylases, have a fiercely debated role in regulating lifespan. In contrast with recent observations, here we find that overexpression of sir-2.1, the ortholog of mammalian SirT1, does extend Caenorhabditis elegans lifespan. Sirtuins mandatorily convert NAD(+)
Gynecologic oncology, 130(1), 25-30 (2013-04-18)
Sorafenib, an oral multikinase inhibitor of the VEGFR/PDGFR/Raf/MEK/ERK pathway, has shown potential activity in patients with recurrent ovarian cancer (OC). One strategy to prolong disease control and survival in patients with OC is maintenance therapy after achieving a complete response.
商品
rganoid culture products to generate tissue and stem cell derived 3D brain, intestinal, gut, lung and cancer tumor organoid models.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门